Eli Lilly and Company (NYSE:LLY) Shares Acquired by Laraway Financial Advisors Inc

Laraway Financial Advisors Inc raised its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 316.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 11,969 shares of the company's stock after acquiring an additional 9,097 shares during the period. Eli Lilly and Company makes up approximately 6.9% of Laraway Financial Advisors Inc's holdings, making the stock its 2nd biggest holding. Laraway Financial Advisors Inc's holdings in Eli Lilly and Company were worth $9,240,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also made changes to their positions in LLY. LifePlan Investment Advisors Inc. increased its stake in shares of Eli Lilly and Company by 4.6% during the fourth quarter. LifePlan Investment Advisors Inc. now owns 318 shares of the company's stock worth $246,000 after purchasing an additional 14 shares in the last quarter. Lionshead Wealth Management LLC acquired a new stake in Eli Lilly and Company during the 4th quarter worth approximately $453,000. Integral Health Asset Management LLC lifted its holdings in Eli Lilly and Company by 280.0% during the 4th quarter. Integral Health Asset Management LLC now owns 38,000 shares of the company's stock worth $29,336,000 after buying an additional 28,000 shares in the last quarter. Investor s Fiduciary Advisor Network LLC purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at approximately $2,482,000. Finally, Janus Henderson Group PLC increased its position in shares of Eli Lilly and Company by 11.1% in the 4th quarter. Janus Henderson Group PLC now owns 4,484,543 shares of the company's stock valued at $3,462,267,000 after purchasing an additional 449,460 shares during the last quarter. 82.53% of the stock is currently owned by institutional investors and hedge funds.

Eli Lilly and Company Trading Down 4.0%

Shares of Eli Lilly and Company stock traded down $29.87 during trading on Wednesday, hitting $716.19. 7,544,764 shares of the company were exchanged, compared to its average volume of 3,573,309. The firm has a market capitalization of $678.76 billion, a P/E ratio of 61.16, a price-to-earnings-growth ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 1-year low of $677.09 and a 1-year high of $972.53. The firm's fifty day moving average price is $804.15 and its 200 day moving average price is $808.91. The company has a debt-to-equity ratio of 2.00, a current ratio of 1.15 and a quick ratio of 0.97.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.64 by ($1.30). The business had revenue of $12.73 billion during the quarter, compared to analyst estimates of $12.77 billion. Eli Lilly and Company had a net margin of 23.51% and a return on equity of 85.24%. Eli Lilly and Company's revenue for the quarter was up 45.2% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $2.58 earnings per share. As a group, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, June 10th. Shareholders of record on Friday, May 16th will be paid a $1.50 dividend. This represents a $6.00 annualized dividend and a yield of 0.84%. The ex-dividend date is Friday, May 16th. Eli Lilly and Company's payout ratio is 48.82%.

Insider Transactions at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of the firm's stock in a transaction that occurred on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total value of $818,240.00. Following the completion of the sale, the chief accounting officer now directly owns 5,840 shares of the company's stock, valued at $4,778,521.60. This trade represents a 14.62% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 0.13% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on the stock. Cantor Fitzgerald started coverage on shares of Eli Lilly and Company in a research report on Tuesday, April 22nd. They set an "overweight" rating and a $975.00 price objective on the stock. Guggenheim reiterated a "buy" rating on shares of Eli Lilly and Company in a research note on Thursday, May 1st. Wells Fargo & Company restated an "overweight" rating on shares of Eli Lilly and Company in a research report on Thursday, May 1st. The Goldman Sachs Group raised shares of Eli Lilly and Company from a "neutral" rating to a "buy" rating and cut their price objective for the company from $892.00 to $888.00 in a research report on Tuesday, April 8th. Finally, Hsbc Global Res lowered shares of Eli Lilly and Company from a "strong-buy" rating to a "moderate sell" rating in a research report on Monday, April 28th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating and nineteen have assigned a buy rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $1,002.80.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.